Beta-Amyloid (1-11)Amyloidogenic peptide CAS# 190436-05-6 |
2D Structure
- Amyloid β-Peptide (10-20) (human)
Catalog No.:BCC1026
CAS No.:152286-31-2
- Amyloid β-Protein (1-15)
Catalog No.:BCC1003
CAS No.:183745-81-5
- Myelin Basic Protein (68-82), guinea pig
Catalog No.:BCC1020
CAS No.:98474-59-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 190436-05-6 | SDF | Download SDF |
PubChem ID | 71317263 | Appearance | Powder |
Formula | C56H76N16O22 | M.Wt | 1325.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Sequence | H2N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-OH | ||
Chemical Name | (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid | ||
SMILES | CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC2=CN=CN2)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NCC(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)N | ||
Standard InChIKey | AGNCCPVJIGFHDN-BVISTOLDSA-N | ||
Standard InChI | InChI=1S/C56H76N16O22/c1-27(64-47(85)32(57)21-44(80)81)46(84)66-34(13-15-42(76)77)50(88)69-37(18-28-6-3-2-4-7-28)52(90)67-33(8-5-17-61-56(58)59)49(87)70-38(20-30-23-60-26-63-30)53(91)71-39(22-45(82)83)54(92)72-40(25-73)48(86)62-24-41(75)65-36(19-29-9-11-31(74)12-10-29)51(89)68-35(55(93)94)14-16-43(78)79/h2-4,6-7,9-12,23,26-27,32-40,73-74H,5,8,13-22,24-25,57H2,1H3,(H,60,63)(H,62,86)(H,64,85)(H,65,75)(H,66,84)(H,67,90)(H,68,89)(H,69,88)(H,70,87)(H,71,91)(H,72,92)(H,76,77)(H,78,79)(H,80,81)(H,82,83)(H,93,94)(H4,58,59,61)/t27-,32-,33-,34-,35-,36-,37-,38-,39-,40-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Beta-Amyloid (1-11) Dilution Calculator
Beta-Amyloid (1-11) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Beta-amyloid (1-11) (Abeta or Aβ) (C56H76N16O22) is a peptide with the sequence H-{Asp}{Ala}{Glu}{Phe}{Arg}{His}{Asp}{Ser}{Gly}{Tyr}{Glu}-OH,which is processed from the Amyloid precursor protein.
- 17β-Benzoyloxy-androsta-1,4-dien-3-one
Catalog No.:BCC8443
CAS No.:19041-66-8
- SLIGKV-NH2
Catalog No.:BCC3959
CAS No.:190383-13-2
- Orientanol A
Catalog No.:BCN4064
CAS No.:190381-82-9
- 3-Butyryloxytropane
Catalog No.:BCN1924
CAS No.:19038-34-7
- Sarracine N-oxide
Catalog No.:BCN2022
CAS No.:19038-27-8
- 7-Hydroxy-4-Methyl-8-Nitrocoumarin
Catalog No.:BCC9210
CAS No.:19037-69-5
- GR 135531
Catalog No.:BCC6836
CAS No.:190277-13-5
- Bripiodionene
Catalog No.:BCN1831
CAS No.:190265-70-4
- Spiratisanin C
Catalog No.:BCN6975
CAS No.:1902173-22-1
- Spiratisanin B
Catalog No.:BCN6976
CAS No.:1902173-19-6
- Spiratisanin A
Catalog No.:BCN6977
CAS No.:1902173-16-3
- Demethoxyencecalin
Catalog No.:BCN1175
CAS No.:19013-07-1
- AT 1015
Catalog No.:BCC6194
CAS No.:190508-50-0
- Dioscin
Catalog No.:BCN6273
CAS No.:19057-60-4
- Prosapogenin A
Catalog No.:BCN2582
CAS No.:19057-67-1
- Ac-Gly-OEt
Catalog No.:BCC2944
CAS No.:1906-82-7
- Ro 32-3555
Catalog No.:BCC2377
CAS No.:190648-49-8
- Bepotastine Besilate
Catalog No.:BCC4538
CAS No.:190786-44-8
- Gracillin
Catalog No.:BCN5360
CAS No.:19083-00-2
- Isocupressic acid
Catalog No.:BCN1177
CAS No.:1909-91-7
- Triptocallic acid A
Catalog No.:BCN1176
CAS No.:190906-61-7
- Calystegine C2
Catalog No.:BCN1878
CAS No.:190957-44-9
- Benzyl 4-Oxo-1-piperidinecarboxylate
Catalog No.:BCC8870
CAS No.:19099-93-5
- Salvigenin
Catalog No.:BCN1178
CAS No.:19103-54-9
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.[Pubmed:17545160]
J Biol Chem. 2007 Aug 3;282(31):22376-86.
Different strategies proposed as therapy for Alzheimer disease (AD) have aimed to reduce the level of toxic forms of A beta peptide in the brain. Here, we directly analyze the therapeutic utility of the polyclonal anti-A beta(1-11) antibody induced in 3xTg-AD mice vaccinated with the second generation prototype epitope vaccine. Substoichiometric concentrations of purified anti-A beta(1-11) antibody prevented aggregation of A beta(42) and induced disaggregation of preformed A beta(42) fibrils down to nonfilamentous and nontoxic species. Anti-A beta(1-11) antibody delayed A beta(42) oligomer formation but ultimately appeared to stabilize nonfibrillar conformations, including oligomer-like assemblies. The reduced oligomer-mediated cytotoxicity observed upon preincubation of A beta oligomers with the anti-A beta(1-11) antibody in the absence of oligomer disaggregation suggests a possible oligomer rearrangement in the presence of the antibody. These in vitro observations suggest that preventive vaccination may protect from AD or may delay the onset of the disease, whereas therapeutic vaccination cannot disrupt the toxic oligomers and may only minimally alleviate preexisting AD pathology.